Skip to main content
Year archive

Kuros Biosciences Ltd. — 2022 filings

All 29 regulatory filings released by Kuros Biosciences Ltd. (KURN) in 2022, sourced directly from the official regulator.

29 Filings
2022 Period
2022 filings (29)
Filing Released Lang
Kuros Biosciences Completes Enrollment of Randomized Stage of Phase 2 Trial for Fibrin-PTH
Regulatory Filings
2022-11-23 English
Kuros Biosciences Completes Enrollment of Randomized Stage of Phase 2 Trial for Fibrin-PTH
Regulatory Filings
2022-11-23 English
Kuros Biosciences completes enrolment in Level 1 clinical study of MagnetOs Granules
Regulatory Filings
2022-11-02 English
Kuros Biosciences completes enrolment in Level 1 clinical study of MagnetOs Granules
Earnings Release Q4 2022
2022-11-02 English
Kuros reports 73% increase in MagnetOs sales in first nine months of 2022
Earnings Release 9M 2022
2022-10-26 English
Kuros reports 73% increase in MagnetOs sales in first nine months of 2022
Earnings Release 9M 2022
2022-10-26 English
Kuros Biosciences awarded 2022 Spine Technology Award for MagnetOs Flex Matrix by Orthopedics This Week
Regulatory Filings
2022-10-19 English
Kuros Biosciences awarded 2022 Spine Technology Award for MagnetOs Flex Matrix by Orthopedics This Week
Regulatory Filings
2022-10-19 English
Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting
Regulatory Filings
2022-10-11 English
Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting
Investor Presentation
2022-10-11 English
Kuros Biosciences Appoints Chris Fair as Chief Operating Officer
Board/Management Information
2022-10-03 English
Kuros Biosciences Appoints Chris Fair as Chief Operating Officer
Board/Management Information
2022-10-03 English
Kuros Biosciences announces successful CHF 6.0 million private placement
Share Issue/Capital Change
2022-09-15 English
Kuros Biosciences announces successful CHF 6.0 million private placement
Share Issue/Capital Change
2022-09-15 English
Kuros Biosciences MagnetOs Bone Graft Successfully Achieves Three Key Milestones
Earnings Release Q3 2022
2022-08-23 English
Kuros Biosciences reports results for the first six months of 2022
Report Publication Announcement H1 2022
2022-08-09 English
Kuros Biosciences reports results for the first six months of 2022
Earnings Release H1 2022
2022-08-09 English
Annual General Meeting of Kuros Biosciences approves all resolutions
AGM Information
2022-06-08 English
Annual General Meeting of Kuros Biosciences approves all resolutions
AGM Information
2022-06-08 English
Kuros Biosciences: Completion of the acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals triggers a $5 million milestone payment
M&A Activity
2022-06-02 English
Kuros Biosciences: Completion of the acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals triggers a $5 million milestone payment
M&A Activity
2022-06-02 English
Kuros Biosciences announces favorable preliminary results of MagnetOs as standalone alternative to autograft in first randomized controlled trial
Regulatory Filings
2022-05-31 English
Kuros Biosciences announces favorable preliminary results of MagnetOs as standalone alternative to autograft in first randomized controlled trial
Regulatory Filings
2022-05-31 English
Kuros Biosciences announces commercial launch of MagnetOs Easypack Putty in the U.S.
Regulatory Filings
2022-05-18 English
Kuros Biosciences continues strong commercial roll-out of MagnetOs bone graft
Earnings Release Q1 2022
2022-04-27 English
Kuros Biosciencess MagnetOs Flex Matrix Cleared by FDA for Spinal Indications
Regulatory Filings
2022-04-21 English
Kuros Biosciences reports results for the full year 2021
Earnings Release FY 2021
2022-03-16 English
Kuros Biosciencess MagnetOs Granules cleared by FDA for expanded spinal indications
Regulatory Filings
2022-02-03 English
Kuros Biosciences publishes first-in-human clinical data for Fibrin-PTH (KUR-113) in treatment of open tibial shaft fractures
Legal Proceedings Report
2022-01-20 English